

# Combined cellular immunotherapy and chemotherapy improves the prognosis of patients with epithelial ovarian cancer

Department of Gynecology, Sun Yat-Sen University Cancer Center






## **Background**


- 1. Cytokine-induced killer (CIK) cells are demonstrated to have potent cytolytic effect against ovarian cancer cells *in vitro* and *in vivo*.
  - 2. The clinical efficacy of maintenance therapy of CIK cells in patients with epithelial ovarian cancer (EOC) after first-line treatment remains unclear.

### Results

1. Phenotypic analysis of immune cells after expansion and Characteristics of Cultured CIK cells.




The percentage of CIK cells (CD3+CD8+D56+) after 14-d induction from the patient.




The phenotype of the autologous CIK cells after culturing at day 14th from each patient was characterized by flow cytometry using four-color fluorescence. The positive rates of CD3+, CD3+CD4+, CD3+CD8+, CD3-CD56+, CD3+CD56+ are shown.


#### 2. CIT prolonged survival of patients with EOC




# 3. Subgroup analysis to estimate the benefits of OS from adjuvant CIT.



# 4. Effects of CIK cell phenotype on survival in the patients.



#### CIK cell treatment assignment procedure



### **Conclusions**

Adjuvant CIT with CIK cells, especially when comprised of more CD8<sup>+</sup>T cells or NKT cells, is an effective therapeutic approach to prolonging the survival of EOC patients.